10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 4, 1998, Pages 444-452

  Dalén, Per ^a   Dahl, Marja Liisa ^a   Bernal Ruiz, Maria Luisa ^a   Nordin, Jan ^a   Bertilsson, Leif ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; NORTRIPTYLINE;

ADULT; ALLELE; ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SALIVATION; SEDATION; VOLUNTEER;

EID: 0031949132     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90040-6     Document Type: Article

References (35)

1. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
2. Tucker GT, Silas JH, Iyun AO, Lennard MS, Smith AJ. Polymorphic hydroxylation of debrisoquine [letter]. Lancet 1977;2:718.
3. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979;16:183-7.
4. Bertilsson L, Dahl ML, Ingelman-Sundberg M, Johansson I, Sjöqvist F. Interindividual and interethnic differences in polymorphic drug oxidation: implications for drug therapy with focus on psychoactive drugs. In: Pacifici GM, Fracchia GN, editor. Advances in drug metabolism in man. Luxembourg: European Commission; 1995. p. 85-136.
5. Eichelbaum M, Gross S. The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992. p. 625-48.
6. Bertilsson L, Dahl ML. Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 1996;5:200-23.
7. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
8. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102-5.
9. Steiner E, Iselius L, Alván G, Lindsten J, Sjöqvist F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 1985;38:394-401.
10. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin [erratum appears in Clin Pharmacol Ther 1994;55:648]. Clin Pharmacol Ther 1992;51:388-97.
11. Bertilsson L, Åberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985;7:478-80.
12. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
13. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90:11825-9.
14. Bertilsson L, Dahl ML, Sjöqvist F, Åberg-Wistedt A, Humble M, Johansson I, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine [letter]. Lancet 1993;341:63.
15. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-20.
16. Agúndez JA, Ledesma MC, Ladero JM, Benítez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995;57:265-9.
17. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996;278:441-6.
18. Dalén P, Frengell C, Dahl ML, Sjöqvist F. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997; 19:543-4.
19. Dahl ML, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992;51:12-7.
20. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991;10:545-58.
21. Alexanderson B, Borgå O. Urinary excretion of nortriptyline and five of its metabolites in man after single and multiple oral doses. Eur J Clin Pharmacol 1973; 5:174-80.
22. Bertilsson L, Alexanderson B. Stereospecific hydroxylation of nortriptyline in man in relation to interindividual differences in its steady-state plasma level. Eur J Clin Pharmacol 1972;4:201-5.
23. Mellström B, Bertilsson L, Säwe J, Schulz HU, Sjöqvist F. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981;30:189-93.
24. Nordin C, Siwers B, Benitez J, Bertilsson L. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients: relationship to the debrisoquine hydroxylation metabolic ratio. Br J Clin Pharmacol 1985;19:832-5.
25. Dahl ML, Nordin C, Bertilsson L. Enantioselective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline. Ther Drug Monit 1991;13:189-94.
26. Bertilsson L, Mellström B, Sjöqvist F. Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. Life Sci 1979;25:1285-92.
27. Wagner A, Ekqvist B, Bertilsson L, Sjöqvist F. Weak binding of 10-hydroxymetabolites of nortriptyline to rat brain muscarinic acetylcholine receptors. Life Sci 1984;35:1379-83.
28. Nordin C, Bertilsson L, Otani K, Widmark A. Little anticholinergic effect of E-10-hydroxynortriptyline compared with nortriptyline in healthy subjects. Clin Pharmacol Ther 1987;41:97-102.
29. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
30. Borgå O, Palmér L, Sjöqvist F, Holmstedt B. Mass fragmentography used in quantitative analysis of drugs and endogenous compounds in biological fluids. Proceedings of the Fifth International Pharmacology Congress; July 23-28, 1973; San Francisco, p. 56-68.
31. Bertilsson L, Nordin C, Otani K, Resul B, Scheinin M, Siwers B, et al. Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects. Clin Pharmacol Ther 1986;40:261-7.
32. Kirk R. Experimental design: procedures for the behavioral sciences. Belmont (CA): Wadsworth Publishing; 1968. p. 65.
33. Freyschuss U, Sjöqvist F, Tuck D, Åsberg M. Circulatory effects in man of nortriptyline, a tricyclic antidepressant drug. Pharmacol Clin 1970;2:68-71.
34. Dahl-Puustinen ML, Perry TL, Dumont E, von Bahr C, Nordin C, Bertilsson L. Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings. Clin Pharmacol Ther 1989;45:650-6.
35. Jang I, Shin J, Shin S, Kim JJ, Woo JI, Lee YS, et al. Assessment of the relationship between plasma nortriptyline concentration and inhibition of salivation: single-dose study. Asia Pac J Pharmacol 1991;6:249-54.